NEW YORK (GenomeWeb) – Genomic Prediction has raised $4.5 million through the sale of preferred stock in a financing round led by Nimble Ventures, the company said today. New investor PeopleFund also joined with Genomic Prediction's early investors.
The North Brunswick, New Jersey-based firm offers tests geared toward patients undergoing in vitro fertilization. It offers a next-generation sequencing-based test for chromosomal aneuploidies, gSeq, as well as an NGS-based test to screen for monogenic and polygenic diseases, EPgT. The gSeq test costs $150 per patient plus an additional $200 for each embryo that is screened, while EPgT costs $1,000, plus $400 per embryo.
The company plans to use the funding to expand its sales team and to further invest in data science. The firm received approval from the New Jersey Department of Health Clinical Laboratory Improvement Services to offer its two preimplantation genetic tests for monogenic disorders and polygenic disorders last September.
"Our cost-effective methodology of polygenic scoring builds on old technology from industrial agriculture, but we are the first in history to develop this technology to protect the human embryo," Genomic Prediction CEO Laurent Tellier said in a statement.